<DOC>
	<DOCNO>NCT01617122</DOCNO>
	<brief_summary>This protocol design ascertain whether bacteriophage 0X174 neoantigen safe effective antigen use evaluation primary secondary immune response . Bacteriophage 0X174 give intravenously 2 billion PFU/Kg body weight ; small blood specimen 3-5 ml ( 1 teaspoon ) collect 15 minute , 7 day , 14 day , 28 day . Blood collect interval follow administration bacteriophage number phage/ml determine agar overlay method use suspension E. coli C serially dilute patient 's serum . Phage-specific IgG IgM measure neutralization assay . Capacity switch IgM IgG determine .</brief_summary>
	<brief_title>Evaluate Bacteriophage Useful Immunogen Patients With Primary Immune Deficiency Diseases ( PIDD )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<criteria>1. subject/parent guardian willing sign consent adhere study schedule 2. know suspected primary immune deficiency 1. pregnancy 2. breastfeed 3. unwilling sign consent adhere study schedule 4 . &lt; 2 yrs age &gt; 85 yrs age 5. previous reaction vaccine</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>PID</keyword>
	<keyword>PIDD</keyword>
	<keyword>antibody deficiency</keyword>
	<keyword>CVID</keyword>
	<keyword>recurrent infection</keyword>
</DOC>